Eurasian J Med. 2026 Jan 10;58(1):1-7. doi: 10.5152/eurasianjmed.2026.25967.
ABSTRACT
BACKGROUND: Knee osteoarthritis (KOA) is a prevalent degenerative joint disease causing pain and functional impairment. Emerging regenerative therapies, including platelet-rich plasma (PRP) and concentrated growth factor (CGF), have shown promise in managing KOA. This study evaluates the short-term efficacy of combined ozone-PRP therapy versus CGF injections in patients with mild to moderate KOA.
METHODS: This retrospective, cross-sectional study analyzed data from 49 patients (94 knees) treated with either ozone-PRP (26 patients, 50 knees) or CGF (23 patients, 44 knees) injections. Pain and function were assessed using the Visual Analogue Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) before and 1 month after treatment.
RESULTS: Both groups demonstrated significant improvements in VAS and WOMAC scores posttreatment (P < .001). However, inter-group comparisons revealed no statistically significant differences in pain reduction or functional improvement (P > .05). In the CGF group, greater pain reduction was observed compared to ozone-PRP (P = .028), while no between-group differences were found in WOMAC pain, stiffness, function, or total scores (P = .298, P = .066, P = .110, and P = .077, respectively).
CONCLUSION: Both ozone-PRP and CGF injections are effective in reducing pain and improving function in patients with mild to moderate knee osteoarthritis in the short term; however, although CGF provides greater pain reduction, the overall WOMAC outcomes are comparable, and the 2 methods may be used interchangeably based on their respective advantages and clinical considerations. Cite this article as: Ayık B, Sarı.imen G, Bakılan F, Armağan O. Comparative Short-Term Efficacy of Combined Ozone and Platelet-Rich Plasma versus Concentrated Growth Factor in the Treatment of Knee Osteoarthritis. The Eurasian Journal of Medicine 2026, 58(1), 0967, doi: 10.5152/eurasianjmed.2026.25967.
PMID:41578819 | DOI:10.5152/eurasianjmed.2026.25967
